$ZJYL
Jin Medical International Ltd. Stock $zjyl

$zjyl Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 20-F Financial Statement

#000121390024036700 Filed on April 26, 2024

Income Statement

Concept	2023 Q3	2023	2022 Q3
Revenue	$19.82M	$19.82M	$19.19M
YoY Change	3.29%	3.29%	-7.58%
Cost Of Revenue	$13.04M	$13.04M	$12.99M
YoY Change	0.34%	0.34%	-9.8%
Gross Profit	$6.785M	$6.785M	$6.199M
YoY Change	9.46%	9.46%	-2.56%
Gross Profit Margin	34.23%	34.23%	32.3%
Selling, General & Admin	$2.375M	$2.375M	$2.175M
YoY Change	9.16%	9.16%	0.59%
% of Gross Profit	35.0%	35.0%	35.1%
Research & Development	$1.543M	$1.543M	$1.893M
YoY Change	-18.47%	-18.47%	20.78%
% of Gross Profit	22.74%	22.74%	30.53%
Depreciation & Amortization	$111.4K	$225.9K	$216.9K
YoY Change	-48.64%	-37.7%	-37.42%
% of Gross Profit	1.64%	3.33%	3.5%
Operating Expenses	$3.918M	$3.918M	$4.068M
YoY Change	-3.7%	-3.7%	9.07%
Operating Profit	$2.867M	$2.867M	$2.131M
YoY Change	34.58%	34.58%	-19.04%
Interest Expense	$132.3K	$132.0K	$368.0K
YoY Change	-64.06%	-64.13%	583.13%
% of Operating Profit	4.61%	4.6%	17.27%
Other Income/Expense, Net	$222.4K	$222.0K	$244.1K
YoY Change	-8.9%	-9.06%	25.2%
Pretax Income	$3.222M	$3.222M	$2.743M
YoY Change	17.48%	17.48%	-4.78%
Income Tax	$343.7K	$343.7K	$36.11K
% Of Pretax Income	10.67%	10.67%	1.32%
Net Earnings	$2.878M	$2.878M	$2.707M
YoY Change	6.34%	6.34%	2.84%
Net Earnings / Revenue	14.52%	14.52%	14.1%
Basic Earnings Per Share		$0.02
Diluted Earnings Per Share	$0.02	$0.02	$0.34
COMMON SHARES
Basic Shares Outstanding	155.9M shares	145.1M shares
Diluted Shares Outstanding		145.6M shares

Balance Sheet

Concept	2023 Q3	2023	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.70M	$16.70M	$7.069M
YoY Change	136.22%	136.22%	23.44%
Cash & Equivalents	$6.930M		$4.793M
Short-Term Investments	$9.769M	$9.769M	$2.276M
Other Short-Term Assets	$864.0K	$864.0K	$857.9K
YoY Change	0.71%	0.71%	4.51%
Inventory	$5.053M	$5.053M	$6.724M
Prepaid Expenses
Receivables	$3.283M	$4.231M	$4.084M
Other Receivables	$28.85K	$4.270M	$167.7K
Total Short-Term Assets	$31.12M	$31.12M	$18.90M
YoY Change	64.61%	64.61%	-2.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.481M	$1.481M	$1.628M
YoY Change	-9.04%	-9.03%	-22.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$152.0K	$152.0K	$245.2K
YoY Change	-38.01%	-38.01%	34.21%
Total Long-Term Assets	$1.788M	$1.787M	$2.036M
YoY Change	-12.22%	-12.25%	-17.92%
TOTAL ASSETS
Total Short-Term Assets	$31.12M	$31.12M	$18.90M
Total Long-Term Assets	$1.788M	$1.787M	$2.036M
Total Assets	$32.90M	$32.90M	$20.94M
YoY Change	57.14%	57.13%	-4.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.391M	$3.710M	$4.507M
YoY Change	-24.77%	-17.69%	-25.74%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$4.113M	$4.113M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.924M	$8.924M	$5.704M
YoY Change	56.46%	56.46%	-27.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.924M	$8.924M	$5.704M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$8.924M	$8.924M	$5.704M
YoY Change	56.46%	56.46%	-27.54%
SHAREHOLDERS EQUITY
Retained Earnings	$16.93M		$14.41M
YoY Change	17.48%
Common Stock	$7.797K		$6.750K
YoY Change	15.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.98M	$23.98M	$15.24M
YoY Change
Total Liabilities & Shareholders Equity	$32.90M	$32.90M	$20.94M
YoY Change	57.14%	57.13%	-4.39%

Cashflow Statement

Concept	2023 Q3	2023	2022 Q3
OPERATING ACTIVITIES
Net Income	$2.878M	$2.878M	$2.707M
YoY Change	6.34%	6.34%	2.84%
Depreciation, Depletion And Amortization	$111.4K	$225.9K	$216.9K
YoY Change	-48.64%	-37.7%	-37.42%
Cash From Operating Activities	$362.9K	$3.106M	$1.632M
YoY Change	-77.76%	96.53%	-72.07%
INVESTING ACTIVITIES
Capital Expenditures	$102.9K	$113.9K	$26.04K
YoY Change	295.16%	183.64%	-39.27%
Acquisitions
YoY Change
Other Investing Activities	-$553.5K	-$7.616M	-$54.05K
YoY Change	924.05%	9333.12%	-94.73%
Cash From Investing Activities	-$656.5K	-$7.730M	-$80.08K
YoY Change	719.81%	6293.92%	-92.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.189M	$6.911M	128.3K
YoY Change	-1026.75%	5570.95%	-104.47%
NET CHANGE
Cash From Operating Activities	362.9K	$3.106M	1.632M
Cash From Investing Activities	-656.5K	-$7.730M	-80.08K
Cash From Financing Activities	-1.189M	$6.911M	128.3K
Net Change In Cash	-1.483M	$2.137M	1.680M
YoY Change	-188.26%	35.11%	-11.82%
FREE CASH FLOW
Cash From Operating Activities	$362.9K	$3.106M	$1.632M
Capital Expenditures	$102.9K	$113.9K	$26.04K
Free Cash Flow	$260.0K	$2.992M	$1.606M
YoY Change	-83.81%	94.25%	-72.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41661
CY2023	dei	Entity Registrant Name EntityRegistrantName	Jin Medical International Ltd.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	No. 33 Lingxiang Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Wujin District
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Changzhou City
CY2023	dei	Entity Address Country EntityAddressCountry	CN
CY2023	dei	Security12b Title Security12bTitle	Ordinary shares, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	ZJYL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	155947100	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Name AuditorName	Audit Alliance LLP
CY2023	dei	Auditor Location AuditorLocation	Singapore
CY2023	dei	Auditor Firm AuditorFirmId	3487
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6929508	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4792632	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	9768835	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	2276158	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3283266	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3830876	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	5053136	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	6724415	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	892597	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	989336	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	31115815	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	18903147	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1480796	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1627962	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	154364	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	163213	usd
CY2023Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	152475	usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	245212	usd
CY2023Q3	us-gaap	Assets Assets	32903450	usd
CY2022Q3	us-gaap	Assets Assets	20939534	usd
CY2023Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	4113000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3391079	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4113622	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	318500	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	393760	usd
CY2023Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	710099	usd
CY2022Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	830305	usd
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	271423	usd
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	248090	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8924345	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5703843	usd
CY2023Q3	us-gaap	Liabilities Liabilities	8924345	usd
CY2022Q3	us-gaap	Liabilities Liabilities	5703843	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	155947100	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	155947100	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135000000	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	7797	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	6750	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6437179	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	79810	usd
CY2023Q3	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	2010890	usd
CY2022Q3	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	1651422	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	16927605	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	14408843	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1404366	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-911134	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	23979105	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	15235691	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32903450	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20939534	usd
CY2023	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	18799099	usd
CY2022	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	18079518	usd
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	20107213	usd
CY2023	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	1022358	usd
CY2022	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	1111023	usd
CY2021	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	657060	usd
CY2023	us-gaap	Revenues Revenues	19821457	usd
CY2022	us-gaap	Revenues Revenues	19190541	usd
CY2021	us-gaap	Revenues Revenues	20764273	usd
CY2023	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	12856556	usd
CY2022	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	12832570	usd
CY2021	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	14178081	usd
CY2023	cik0000183782	Business And Sales Related Tax BusinessAndSalesRelatedTax	180067	usd
CY2022	cik0000183782	Business And Sales Related Tax BusinessAndSalesRelatedTax	159453	usd
CY2021	cik0000183782	Business And Sales Related Tax BusinessAndSalesRelatedTax	225056	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	13036623	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	12992023	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	14403137	usd
CY2023	us-gaap	Gross Profit GrossProfit	6784834	usd
CY2022	us-gaap	Gross Profit GrossProfit	6198518	usd
CY2021	us-gaap	Gross Profit GrossProfit	6361136	usd
CY2023	us-gaap	Selling Expense SellingExpense	453311	usd
CY2022	us-gaap	Selling Expense SellingExpense	402013	usd
CY2021	us-gaap	Selling Expense SellingExpense	488998	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1921367	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1773449	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1673776	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1542894	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1892532	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1566860	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	3917572	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4067994	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	3729634	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	2867262	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	2130524	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	2631502	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	182682	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	181605	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-9492	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-50406	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	186394	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	63355	usd
CY2023	us-gaap	Other Income OtherIncome	222399	usd
CY2022	us-gaap	Other Income OtherIncome	244115	usd
CY2021	us-gaap	Other Income OtherIncome	194982	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	354675	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	612114	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	248845	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3221937	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2742638	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2880347	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	343707	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36111	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	248641	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2878230	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2706527	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	2631706	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-493232	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1499721	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	594716	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2384998	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1206806	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3226422	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145136980	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135000000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135000000	shares
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10802463	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	2631706	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	594716	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	14028885	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2706527	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1499721	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15235691	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8000000	usd
CY2023	cik0000183782	Cost Directly Related To The Initial Public Offering CostDirectlyRelatedToTheInitialPublicOffering	1978222	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	378840	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	42202	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2878230	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-493232	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	23979105	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2878230	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2706527	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	2631706	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	225902	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	362597	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	346608	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	6856	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-13367	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	120334	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	28943	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-108706	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	89603	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-86023	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1663	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-348730	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-241922	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-159376	usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	724809	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-91735	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-2918346	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1555441	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	504387	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-458607	usd
CY2021	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	-18481	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	716356	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-430744	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	810918	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-646886	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-810342	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-369080	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-67705	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-281189	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	34650	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-102949	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-755371	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	647856	usd
CY2023	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	123204	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	30520	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	155500	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-95338	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3106403	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1580656	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5843292	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	113937	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40166	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42881	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	10138	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	12052957	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	5646200	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4956930	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	4426508	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	5201034	usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	4147200	usd
CY2022	cik0000183782	Repayment Ofpayments Of Advances Made To Related Parties RepaymentOfpaymentsOfAdvancesMadeToRelatedParties	-364428	usd
CY2021	cik0000183782	Repayment Ofpayments Of Advances Made To Related Parties RepaymentOfpaymentsOfAdvancesMadeToRelatedParties	215029	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7730248	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-120904	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1067640	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	8000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	-1212779	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	336638	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	5672000	usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	768000	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1418000	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	3534336	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-4467240	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	121855	usd
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-103883	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6910619	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	121855	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2870219	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-149898	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-461235	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	103303	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2136876	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1120372	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2008736	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4792632	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3672260	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1663524	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6929508	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4792632	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3672260	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	142730	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	47438	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	302254	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	33618	usd
CY2023	us-gaap	Interest Paid InterestPaid	5319	usd
CY2021	us-gaap	Interest Paid InterestPaid	68777	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	765443	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><span style="background-color: white"><b><i>Uses of estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><span style="background-color: white">In preparing the consolidated financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the valuation of accounts receivable and inventories, useful lives of property, plant and equipment and land use right, the recoverability of long-lived assets, and realization of deferred tax assets. Actual results could differ from those estimates.</span></p>
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	9768835	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	2276158	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	117213	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	107510	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	63736	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	125448	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	114486	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1892532	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1566860	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.50	pure
CY2023	cik0000183782	Capitalization For Lease CapitalizationForLease	10000	usd
CY2023	cik0000183782	Land Use Rights LandUseRights	46 years
CY2023	us-gaap	Revenues Revenues	19821457	usd
CY2022	us-gaap	Revenues Revenues	19190541	usd
CY2021	us-gaap	Revenues Revenues	20764273	usd
CY2023	us-gaap	Revenues Revenues	19821457	usd
CY2022	us-gaap	Revenues Revenues	19190541	usd
CY2021	us-gaap	Revenues Revenues	20764273	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1542894	usd
CY2023	cik0000183782	Value Added Tax Percentage ValueAddedTaxPercentage	0.13	pure
CY2022	cik0000183782	Value Added Tax Percentage ValueAddedTaxPercentage	0.13	pure
CY2021	cik0000183782	Value Added Tax Percentage ValueAddedTaxPercentage	0.13	pure
CY2023	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	1083136	usd
CY2022	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	1061843	usd
CY2021	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	1146137	usd
CY2023Q3	cik0000183782	Foreign Currency Translation Revenue Percentage ForeignCurrencyTranslationRevenuePercentage	0.033	pure
CY2023Q3	cik0000183782	Foreign Currency Translation Net Income Percentage ForeignCurrencyTranslationNetIncomePercentage	0.063	pure
CY2023	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	449954	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	626534	usd
CY2021	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	451465	usd
CY2023	cik0000183782	Accounts Receivable Thirdparty Customers AccountsReceivableThirdpartyCustomers	3408714	usd
CY2022	cik0000183782	Accounts Receivable Thirdparty Customers AccountsReceivableThirdpartyCustomers	3945362	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	125448	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	114486	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	3283266	usd
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	3830876	usd
CY2023	cik0000183782	Accounts Receivable Percentage AccountsReceivablePercentage	0.767	pure
CY2023Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	2500000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	114486	usd
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	96688	usd
CY2023	cik0000183782	Additionsreductions Additionsreductions	119021	usd
CY2022	cik0000183782	Additionsreductions Additionsreductions	28943	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	104735	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-3324	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-11145	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	125448	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	114486	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	2618406	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	3274744	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1613781	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1399074	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	820949	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2050597	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	5053136	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	6724415	usd
CY2023Q3	us-gaap	General And Administrative Costs In Inventory Amount Remaining GeneralAndAdministrativeCostsInInventoryAmountRemaining	901963	usd
CY2022Q3	us-gaap	General And Administrative Costs In Inventory Amount Remaining GeneralAndAdministrativeCostsInInventoryAmountRemaining	803413	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	29885	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	42775	usd
CY2023Q3	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	28861	usd
CY2022Q3	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	51321	usd
CY2022	us-gaap	Depreciation Depreciation	357269	usd
CY2021	us-gaap	Depreciation Depreciation	341245	usd
CY2023Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	28852	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	131449	usd
CY2023	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	803745	usd
CY2022	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	156491	usd
CY2022	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	701396	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	60000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	892597	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	989336	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5239137	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5286684	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3758341	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3658722	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1480796	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1627962	usd
CY2023	us-gaap	Depreciation Depreciation	220951	usd
CY2023Q3	us-gaap	Land Land	220178	usd
CY2022Q3	us-gaap	Land Land	225798	usd
CY2023Q3	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	65814	usd
CY2022Q3	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	62585	usd
CY2023Q3	us-gaap	Land Improvements LandImprovements	154364	usd
CY2022Q3	us-gaap	Land Improvements LandImprovements	163213	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4951	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	5328	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	5363	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4786	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4786	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4786	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4786	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4786	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	130434	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	154364	usd
CY2023Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	4113000	usd
CY2023Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	30000000	cny
CY2023Q3	cik0000183782	Working Capital Period WorkingCapitalPeriod	P1Y
CY2023	us-gaap	Interest Costs Incurred InterestCostsIncurred	5319	usd
CY2021	us-gaap	Interest Costs Incurred InterestCostsIncurred	68777	usd
CY2023	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	4240524	usd
CY2022	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	36257	usd
CY2023Q3	cik0000183782	Deferred Revenue From Related Party DeferredRevenueFromRelatedParty	119120	usd
CY2023Q3	cik0000183782	Due To Related Parties DueToRelatedParties	1124	usd
CY2022Q3	cik0000183782	Due To Related Parties DueToRelatedParties	118066	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5049	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	107661	usd
CY2023	cik0000183782	Revenue From Related Partie RevenueFromRelatedPartie	1022358	usd
CY2022	cik0000183782	Revenue From Related Partie RevenueFromRelatedPartie	1111023	usd
CY2021	cik0000183782	Revenue From Related Partie RevenueFromRelatedPartie	657060	usd
CY2023	us-gaap	Development Profits Nonoperating DevelopmentProfitsNonoperating	2000000	hkd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.15	pure
CY2018Q4	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.15	pure
CY2019Q4	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.15	pure
CY2021Q4	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.15	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.15	pure
CY2023	us-gaap	Dividend Income Securities Operating Taxable DividendIncomeSecuritiesOperatingTaxable	1000000	cny
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.05	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.025	pure
CY2023Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	374530	usd
CY2022Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	270220	usd
CY2021Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	284786	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	254105	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	122133	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	250305	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	89602	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-86022	usd
CY2021	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-1664	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	343707	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36111	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	248641	usd
CY2023Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	144106	usd
CY2022Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	134626	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	19008	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	17173	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	168163	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	259460	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15688	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14248	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	152475	usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	245212	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14248	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13636	usd
CY2023	us-gaap	Deferred Taxes Business Combination Valuation Allowance Available To Reduce Income Tax Expense DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense	1844	usd
CY2022	us-gaap	Deferred Taxes Business Combination Valuation Allowance Available To Reduce Income Tax Expense DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense	2022	usd
CY2023	cik0000183782	Exchange Difference ExchangeDifference	404	usd
CY2022	cik0000183782	Exchange Difference ExchangeDifference	1410	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15688	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14248	usd
CY2023Q3	cik0000183782	Deferred Tax Assets Percentage DeferredTaxAssetsPercentage	1	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.25	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.25	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.25	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Holidays EffectiveIncomeTaxRateReconciliationTaxHolidays	0.116	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Holidays EffectiveIncomeTaxRateReconciliationTaxHolidays	0.099	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Holidays EffectiveIncomeTaxRateReconciliationTaxHolidays	0.099	pure
CY2023	cik0000183782	Effective Income Tax Rate Reconciliation Permanent Difference EffectiveIncomeTaxRateReconciliationPermanentDifference	0.001	pure
CY2022	cik0000183782	Effective Income Tax Rate Reconciliation Permanent Difference EffectiveIncomeTaxRateReconciliationPermanentDifference	0.001	pure
CY2021	cik0000183782	Effective Income Tax Rate Reconciliation Permanent Difference EffectiveIncomeTaxRateReconciliationPermanentDifference	0.046	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.072	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.14	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.112	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.043	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.001	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.001	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.107	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.013	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.086	pure
CY2023Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	263131	usd
CY2022Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	170887	usd
CY2023Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1627	usd
CY2022Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	52474	usd
CY2023Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	6665	usd
CY2022Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	24729	usd
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	271423	usd
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	248090	usd
CY2023	cik0000183782	Cash Deposits With Financial Institutions Outside CashDepositsWithFinancialInstitutionsOutside	1363617	usd
CY2023	cik0000183782	Cash Deposits With Financial Institutions CashDepositsWithFinancialInstitutions	5561070	usd
CY2022	cik0000183782	Cash Deposits With Financial Institutions CashDepositsWithFinancialInstitutions	4785389	usd
CY2022Q4	cik0000183782	Ordinary Shares Surrendered OrdinarySharesSurrendered	265000000	shares
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.4
CY2023Q1	us-gaap	Sale Leaseback Transaction Gross Proceeds Investing Activities SaleLeasebackTransactionGrossProceedsInvestingActivities	8000000	usd
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	6800000	usd
CY2023Q1	cik0000183782	Granted Underwriters Option To Purchase Period GrantedUnderwritersOptionToPurchasePeriod	P45D
CY2023Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	3000000	shares
CY2023Q2	us-gaap	Sale Leaseback Transaction Gross Proceeds Investing Activities SaleLeasebackTransactionGrossProceedsInvestingActivities	378840	usd
CY2023	cik0000183782	Statutory Surplus Percentage StatutorySurplusPercentage	0.10	pure
CY2023	cik0000183782	Reserve Equal Percentage ReserveEqualPercentage	0.50	pure
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	2010890	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	1651422	usd
CY2023	cik0000183782	Restricted Net Assets RestrictedNetAssets	2097449	usd
CY2022	cik0000183782	Restricted Net Assets RestrictedNetAssets	1737982	usd
CY2014Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P20Y
CY2014Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	39000	usd
CY2014Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	250000	cny
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	24099	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	74536	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	82906	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4936	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	165	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	165	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	165	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	165	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1522	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7118	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2023	cik0000183782	Percentage Of Consolidated Net Assets PercentageOfConsolidatedNetAssets	0.25	pure
CY2022Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135000000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135000000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145598860	shares
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies		usd
CY2022	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies		usd
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation		usd
CY2021	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation		usd
CY2023	cik0000183782	Repayment Ofpayments Of Advances Made To Related Parties RepaymentOfpaymentsOfAdvancesMadeToRelatedParties		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Interest Paid InterestPaid		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	us-gaap	Product Warranty Expense ProductWarrantyExpense		usd
CY2022	us-gaap	Product Warranty Expense ProductWarrantyExpense		usd
CY2021	us-gaap	Product Warranty Expense ProductWarrantyExpense		usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs		usd
CY2023	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering		usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent		usd
CY2022	us-gaap	Interest Costs Incurred InterestCostsIncurred		usd
CY2022Q3	cik0000183782	Deferred Revenue From Related Party DeferredRevenueFromRelatedParty		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent		pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent		pure
CY2022	cik0000183782	Cash Deposits With Financial Institutions Outside CashDepositsWithFinancialInstitutionsOutside		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	00000
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001837821

Files In Submission

Name	View Source	Status
0001213900-24-036700-index-headers.html	Edgar Link	pending
0001213900-24-036700-index.html	Edgar Link	pending
0001213900-24-036700.txt	Edgar Link	pending
0001213900-24-036700-xbrl.zip	Edgar Link	pending
cik0000183782-20230930.xsd	Edgar Link	pending
ex15-1_001.jpg	Edgar Link	pending
ex15-1_002.jpg	Edgar Link	pending
ex15-2_001.jpg	Edgar Link	pending
ex15-4_001.jpg	Edgar Link	pending
f20f2023ex1-2_jinmedical.htm	Edgar Link	pending
f20f2023ex11-2_jinmedical.htm	Edgar Link	pending
f20f2023ex12-1_jinmedical.htm	Edgar Link	pending
f20f2023ex12-2_jinmedical.htm	Edgar Link	pending
f20f2023ex13-1_jinmedical.htm	Edgar Link	pending
f20f2023ex13-2_jinmedical.htm	Edgar Link	pending
cik0000183782-20230930_cal.xml	Edgar Link	unprocessable
cik0000183782-20230930_def.xml	Edgar Link	unprocessable
cik0000183782-20230930_lab.xml	Edgar Link	unprocessable
cik0000183782-20230930_pre.xml	Edgar Link	unprocessable
f20f2023ex15-1_jinmedical.htm	Edgar Link	pending
f20f2023ex15-2_jinmedical.htm	Edgar Link	pending
f20f2023ex15-4_jinmedical.htm	Edgar Link	pending
f20f2023ex2-2_jinmedical.htm	Edgar Link	pending
f20f2023ex4-9_jinmedical.htm	Edgar Link	pending
f20f2023ex8-1_jinmedical.htm	Edgar Link	pending
f20f2023ex97-1_jinmedical.htm	Edgar Link	pending
f20f2023_jinmedical.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
image_023.jpg	Edgar Link	pending
image_024.jpg	Edgar Link	pending
image_025.jpg	Edgar Link	pending
image_026.jpg	Edgar Link	pending
image_027.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
f20f2023_jinmedical_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZJYL
Jin Medical International Ltd. Stock $zjyl

2023 Q3 Form 20-F Financial Statement

#000121390024036700 Filed on April 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZJYL Jin Medical International Ltd. Stock $zjyl

2023 Q3 Form 20-F Financial Statement

#000121390024036700 Filed on April 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZJYL
Jin Medical International Ltd. Stock $zjyl